KORU Medical Systems, Inc.

Equities

KRMD

US7599101026

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2024-09-20 EDT 5-day change 1st Jan Change
2.690 USD +4.67% Intraday chart for KORU Medical Systems, Inc. +6.75% +9.57%
LockThis article is reserved for members
To unlock the article, REGISTER!
Vous êtes déja client ? Log In
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q2 Revenue $8.4M, vs. Street Est of $7.6M MT
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Reports Q2 Loss $-0.01, vs. Street Est of $-0.04 MT
KORU Medical Systems, Inc., Q2 2024 Earnings Call, Aug 07, 2024
KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024 CI
KORU Medical Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
KORU Medical Systems Promotes Christopher Pazdan to Chief Operating Officer MT
KORU Medical Systems, Inc Announces Executive Changes CI
Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan MT
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 3000E Growth Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 2000 Growth Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 2500 Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 3000 Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 2000 Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 3000 Growth Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 2000 Dynamic Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Completeness Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 3000E Index CI
KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 2500 Growth Index CI
SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion CI
KORU Medical Systems, Inc. Announces Collaboration with Global Pharmaceutical Company to Initiate Feasibility Study with Its Freedom Infusion System for FDA and EMA Approved Subcutaneous Oncology Biologic Drug CI
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic CI
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q1 Revenue $8.2M, vs. Street Est of $7.5M MT
KORU Medical Systems, Inc., Q1 2024 Earnings Call, May 01, 2024
Chart KORU Medical Systems, Inc.
More charts
Logo KORU Medical Systems, Inc.
KORU Medical Systems, Inc. designs, manufactures, and markets proprietary portable and advanced medical devices primarily for the subcutaneous drug delivery market. The Company is focused on home and specialty infusion solutions. Its focus is primarily concentrated on its mechanical infusion products, the FREEDOM Infusion Systems, which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. The devices are used for infusions administered at home and in alternate care settings. Its infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.
Employees
0
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.690USD
Average target price
3.600USD
Spread / Average Target
+33.83%
Consensus
  1. Stock Market
  2. Equities
  3. KRMD Stock
  4. News KORU Medical Systems, Inc.
  5. Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan